Acrivastine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Seasonal allergic rhinitis; Chronic idiopathic urticaria 8 mg up to tid.
Dosage Details
Oral
Allergic conditions
Adult: 8 mg, as necessary, up to tid.
Child: ≥12 yr Same as adult dose.
Renal Impairment
Severe: Contraindicated.
Administration
May be taken with or without food.
Contraindications
Severe renal impairment.
Special Precautions
Patient w/ porphyria, epilepsy. Renal impairment. Elderly. Pregnancy and lactation.
Adverse Reactions
Anticholinergic effects, GI disturbance, headache, psychomotor impairment, somnolence, dry mouth, rash, blurred vision, urinary retention. Rarely, dizziness, dyspnoea, angioedema.
PO: B (FDA Pregnancy Category B for acrivastine/pseudoephedrine hydrochloride combination.)
Patient Counseling Information
This drug may cause dizziness and somnolence, if affected, do not drive or operate machinery.
Drug Interactions
May produce additional mental depression w/ CNS depressants.
Food Interaction
May produce additional mental depression w/ alcohol.
Action
Description: Acrivastine, an alkylamine, is a second generation antihistamine structurally related to triprolidine. It is a competitive antagonist of H1-receptors but lacks anticholinergic effects.
Onset: 15 min.
Pharmacokinetics:
Absorption: Rapidly absorbed from the GI tract. Time to peak plasma concentration: Approx 1.5 hr.
Distribution: Volume of distribution: Approx 0.5-0.8 L/kg. Plasma protein binding: Approx 50%, mainly to albumin.
Metabolism: Minimally metabolised in the liver into its active metabolite, propionic acid.
Excretion: Via urine (84%) and faeces (13%). Elimination half-life: Approx 2-4 hr.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store at or below 30°C.
ATC Classification
R06AX18 - acrivastine ; Belongs to the class of other antihistamines for systemic use.
Disclaimer: This information is independently developed by MIMS based on Acrivastine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in